Vest Financial LLC Boosts Stock Holdings in Pfizer Inc. $PFE

Vest Financial LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 28.5% during the fourth quarter, Holdings Channel reports. The fund owned 104,713 shares of the biopharmaceutical company’s stock after acquiring an additional 23,242 shares during the period. Vest Financial LLC’s holdings in Pfizer were worth $2,607,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Horizon Financial Services LLC increased its position in shares of Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 645 shares during the period. YANKCOM Partnership acquired a new position in shares of Pfizer during the fourth quarter worth $28,000. Grey Fox Wealth Advisors LLC acquired a new position in shares of Pfizer during the third quarter worth $29,000. True Wealth Design LLC grew its stake in shares of Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 974 shares in the last quarter. Finally, Darwin Wealth Management LLC acquired a new position in shares of Pfizer during the second quarter worth $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on PFE. CICC Research began coverage on shares of Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 target price for the company. Citigroup boosted their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday. Daiwa Securities Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target for the company. in a research report on Thursday, February 12th. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, HSBC boosted their price target on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $28.74.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Late?stage success for ELREXFIO: Pfizer reported Phase 3 MagnetisMM?5 topline results showing a statistically significant, clinically meaningful improvement in progression?free survival for relapsed/refractory multiple myeloma — a clear pipeline and revenue catalyst. Pfizer’s blood cancer drug meets main goal in late-stage trial
• Positive Sentiment: Vyndamax exclusivity extended until 2031: Pfizer reached settlement agreements with generic makers that delay generic entry for its $6.4bn heart?disease drug, protecting near?term revenue and margins for the franchise. Pfizer protects $6.4bn heart disease blockbuster from generics, for now
• Neutral Sentiment: Longer?term R&D tailwinds: the clinical trials market is forecast to expand materially through 2034, which supports the value of Pfizer’s development programs but is a broad industry tailwind rather than a company?specific catalyst. Clinical Trials Market Analysis/Forecasts 2026-2034
• Neutral Sentiment: Technical/short?term momentum mixed: some screens flagged improving RSI, suggesting sentiment may be stabilizing after recent moves. Pfizer among 6 stocks showing bullish RSI upswing
• Negative Sentiment: Near?term earnings concerns: analysts and previews flagged an expected Q1 earnings decline, which can weigh on the stock until the earnings print. Earnings Preview: Pfizer (PFE) Q1 Earnings Expected to Decline
• Negative Sentiment: Small analyst EPS cut: Erste trimmed its FY2027 EPS estimate modestly, adding to short?term downward pressure from lower near?term earnings expectations. Pfizer Stock Profile
• Negative Sentiment: Market reaction and headlines: coverage noting the stock’s decline and settlement news likely prompted short?term profit?taking despite the positive pipeline/patent developments. Pfizer Says Cancer Therapy Beats Standard Therapy In Late-Stage Blood Cancer Study

Pfizer Price Performance

Shares of NYSE:PFE opened at $26.27 on Thursday. The company has a 50-day simple moving average of $27.17 and a 200-day simple moving average of $26.09. Pfizer Inc. has a one year low of $21.97 and a one year high of $28.75. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The stock has a market capitalization of $149.36 billion, a price-to-earnings ratio of 19.31 and a beta of 0.43.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same period in the prior year, the company earned $0.63 earnings per share. The business’s revenue was down 1.2% compared to the same quarter last year. On average, analysts predict that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.5%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio is currently 126.47%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.